中国中医科学院广安门医院 北京 100053
黄蓉,女,在读硕士生
# 张培彤,男,博士,主任医师、教授,博士生导师,E-mail:drzhangpeitong@hotmail.com
纸质出版日期:2022-03-30,
收稿日期:2021-04-10,
移动端阅览
黄蓉, 张培彤, 王璐瑶, 等. 基于恶性肿瘤的分阶段发生发展探讨中医防治策略[J]. 现代中医临床, 2022,29(2):64-68.
Rong HUANG, Peitong ZHANG, Luyao WANG, et al. Prevention and treatment strategies for malignant tumors in traditional Chinese medicine based on the phase-based occurrence and development[J]. Modern Chinese Clinical Medicine, 2022,29(2):64-68.
黄蓉, 张培彤, 王璐瑶, 等. 基于恶性肿瘤的分阶段发生发展探讨中医防治策略[J]. 现代中医临床, 2022,29(2):64-68. DOI: 10.3969/j.issn.2095-6606.2022.02.015.
Rong HUANG, Peitong ZHANG, Luyao WANG, et al. Prevention and treatment strategies for malignant tumors in traditional Chinese medicine based on the phase-based occurrence and development[J]. Modern Chinese Clinical Medicine, 2022,29(2):64-68. DOI: 10.3969/j.issn.2095-6606.2022.02.015.
恶性肿瘤的发生发展是一个长期、分阶段、多种基因突变积累的过程,从中医角度将恶性肿瘤 的发生发展分为癌毒形成、实邪蕴结、正虚邪盛3个阶段,其中癌毒形成是恶性肿瘤发生的先决条件,实邪蕴结是癌前病变的形成阶段,正虚邪盛为癌前病变进一步恶化为原位癌,并向微浸润癌、浸润癌、转移癌渐进式发展阶段。并以此提出恶性肿瘤的中医防治策略,未病时要预防气滞、痰湿、瘀血、癌毒病理产物的形成,建立中西医结合的体检模式,治疗癌前病变时当注重攻邪,既病时应辨正邪盛衰分段论治,瘥后防复时不忘祛除实邪,为中医防治恶性肿瘤提供思路。
A malignant tumor is a process of long-term
phased and multi-gene mutation accumulation. From the perspective of traditional Chinese medicine (TCM)
the occurrence and development of a malignant tumor is divided into three stages: the stage of cancer toxin formation
the stage of excess pathogen accumulation and the stage of deficiency in healthy Qi and exuberance in pathogenic factors. The formation of cancer toxin is a prerequisite for the occurrence of malignant tumors. The stage of excess pathogen accumulation is the formation of precancerous lesions. The stage of deficiency in healthy Qi and exuberance in pathogenic factors is the period when precancerous lesions further deteriorate into carcinoma in situ
and develop gradually to microinvasive carcinoma
invasive carcinoma and metastatic carcinoma. Based on this
this paper puts forward the TCM prevention and treatment strategies for malignant tumors: when not ill
we should prevent the formation of pathological products such as Qi stagnation
phlegm dampness
blood stasis and cancer toxins
and establish the physical examination mode of integrated traditional Chinese and Western medicine. Attention is paid to attacking pathogens when precancerous lesions are treated
the exuberance and debilitation of the healthy qi and pathogenic factors should be distinguished when the disease is already present
and do not forget to eliminate pathogens during recovery
so as to provide ideas for TCM prevention and treatment of malignant tumors.
恶性肿瘤中医病理产物防治分阶段
malignant tumortraditional Chinese medicinepathological productsprevention and treatmentstaging
孙燕.临床肿瘤学高级教程[M].北京:人民军医出版社,2014.
赖鹏华,王彦晖,李鹏程,等.王彦晖教授从“病理产物”论治肿瘤经验[J].中华中医药杂志,2014,29(10):3139-3141.
王彦晖,申秀云.论气滞乃病理产物[J].甘肃中医学院学报,1999,16(4):9-11.
杨士瀛.仁斋直指方论[M].盛维忠,王致谱,傅芳,等,校注.福州:福建科学技术出版社,1989:579.
程海波.癌毒病机理论探讨[J].中医杂志,2014,55(20):1711-1715.
吴深涛.内毒论[J].中医杂志,2017,58(15):1265-1269.
李琦玮,于明薇,王笑民.癌毒理论研究现状[J].中医杂志,2015,56(4):347-350,354.
赵帆,王兰,梁腾霄.中医药学中“毒”的含义和理论探讨[J].现代中医临床,2017,24(1):9-11.
钟霞,焦华琛,李运伦,等.毒邪实质刍议[J].辽宁中医药大学学报,2020,22(5):88-91.
陈实功.外科正宗[M].刘忠恕,张若兰,点校.天津:天津科学技术出版社,1993:160.
周之干.慎斋遗书[M].熊俊,校注.北京:中国中医药出版社,2016:248.
程海波,吴勉华,周红光.周仲瑛从癌毒辨治恶性肿瘤的经验[J].北京中医药,2009,28(11):844-846.
李栋,吴勉华.消癌解毒方加入LPS及CD284对人肝癌细胞SMMC-7721的TLRs/NF-κB信号转导通路等关键基因表达的影响[J].中华中医药杂志,2016,31(11):4693-4698.
刘平,徐静,方媛,等.扶正祛毒汤对大肠癌患者免疫功能影响的研究进展[J].肿瘤药学,2019,9(4):540-543.
KORNILUK A, KOPER O, KEMONA H, et al.From inflammation to cancer[J].Irish Journal of Medical Science(1971-),2017,186(1): 57-62.
程海波,沈卫星.癌毒病机理论与炎癌转变[J].中国中西医结合杂志,2015,35(2):243-246.
李黎,沈波,陈海彬,等.消癌解毒方对H22荷瘤小鼠外周血清转化生长因子β1的影响[J].辽宁中医杂志,2011,38(11):2283-2284.
陈海彬,沈波,李黎,等.消癌解毒方抑制肝癌H22移植瘤的生长及其机制[J].中国肿瘤生物治疗杂志,2011,18(1):28-32.
王俊壹,程海波,周仲瑛.结直肠癌前病变的中医理论探析[J].中医杂志,2018,59(21):1819-1823.
杨良俊,樊湘珍,李嘉丽,等.从癌毒理论探讨托里透毒法治疗胃癌前病变[J].中医杂志,2019,60(23):2013-2016.
张正标,赵新爱,高巧云,等.恶性肿瘤中医证型分布调查与研究[J].世界中西医结合杂志,2019,14(2):261-263,267.
叶乃菁,刘宣,李琦.癌毒转移的中医理论探讨[J].中医杂志,2014,55(3):185-188.
LIOTTA L A, KOHN E C.The microenvironment of the tumor-host interface[J].Nature,2001,411(6835):375-379.
张思奇,胡凯文,周天.脾虚、血瘀及痰饮与乏氧肿瘤微环境研究进展[J].中国中医药信息杂志,2018,25(7):126-129.
沈政洁,程海波,沈卫星,等.肿瘤炎性微环境与“癌毒”病机相关性探讨[J].北京中医药大学学报,2015,38(1):14-17.
孙玲玲,林丽珠.益气除痰方对缺氧微环境下A549细胞上皮间质转化及P4HB表达的影响[J].中药新药与临床药理,2013,24(5):454-457.
李小菊,卢宏达,陈卫群,等.水蛭抑制肿瘤血管生成的作用及其机制[J].肿瘤防治研究,2013,40(1):46-50.
郭利华,赵瑞莲,刘建丽,等.基于国医大师张震疏调理论探讨肿瘤气机郁滞致癌的病机[J].云南中医中药杂志,2020,41(3):103-105.
杨晓蕾,杨超,张钦婷,等.恶性肿瘤患者中医体质类型相关研究[J].辽宁中医药大学学报,2015,17(8):164-166.
宋和平,曹烨民,郭义,等.《中医治未病实践指南》中药茶调理偏颇体质的一致性测评分析[J].西部中医药,2019,32(7):76-79.
吴晶晶.活血祛瘀膏干预女性血瘀体质的临床疗效观察[D].上海:上海中医药大学,2019.
高嘉良.气滞血瘀证诊断量表及其circRNA差异表达研究[D].北京:中国中医科学院,2017.
王婷.四逆散联合化痰消瘀汤剂治疗全胃胃炎伴胃癌前期病变的疗效观察[D].南京:南京医科大学,2018.
赵艳,吴海涛.化痰消瘀方通过调节自噬对大鼠癌前病的改善作用[J].中成药,2020,42(6):1628-1632.
黄名威,吴留成,周帆,等.循环肿瘤细胞参与肿瘤复发转移机制的研究进展[J].中国癌症防治杂志,2018,10(1):51-55.
0
浏览量
17
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构